Existing evidence suggests a severe limitation to the efficacy of ICI in patients with EGFR-mutant NSCLC, especially after developing resistance to tyrosine kinase inhibitor (TKI) (10, 11). Here, EGFR is linked to non-small cell lung carcinoma.